Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 34.14 per share at the end of the most recent trading day (a 2.15% change compared to the prior day closing price) with a volume of 2.01M shares and market capitalization of 3.19B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.

The one-year performance of Fate Therapeutics Inc. stock is -64.34%, while year-to-date (YTD) performance is -41.65%. FATE stock has a five-year performance of 1026.73%. Its 52-week range is between 17.1 and 97.43, which gives FATE stock a 52-week price range ratio of 19.59%

Fate Therapeutics Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of 59.64, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.22%, a ROC of -28.41% and a ROE of -33.75%. The company’s profit margin is -%, its EBITDA margin is -368.80%, and its revenue ttm is $49.71 Million , which makes it $0.51 revenue per share.

Of the last four earnings reports from Fate Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.86 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Strong Buy (1.47), with a target price of $75.73, which is +130.60% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fate Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.16, ATR14 : 2.87, CCI20 : 211.88, Chaikin Money Flow : 0.06, MACD : 1.47, Money Flow Index : 41.79, ROC : 2.40, RSI : 43.33, STOCH (14,3) : 60.76, STOCH RSI : 1.00, UO : 47.16, Williams %R : -39.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $712 349), Bahram Valamehr (Sold 288 340 shares of value $13 310 127 ), Cindy Tahl (Option Excercise at a value of $1 637 500), Cindy Tahl (Sold 276 314 shares of value $14 209 201 ), Edward J. Dulac (Option Excercise at a value of $615 384), Edward J. Dulac (Sold 24 704 shares of value $1 609 193 ), J. Scott Wolchko (Option Excercise at a value of $639 035), J. Scott Wolchko (Sold 264 968 shares of value $12 897 133 ), John D. Mendlein (Option Excercise at a value of $51 446), John D. Mendlein (Sold 32 926 shares of value $1 136 286 ), Karin Jooss (Sold 1 483 shares of value $33 842 ), Mark Plavsic (Sold 3 719 shares of value $91 525 ), Robert M. Hershberg (Sold 672 shares of value $15 288 ), Shefali Agarwal (Sold 1 648 shares of value $36 809 ), Timothy P. Coughlin (Sold 1 439 shares of value $32 824 ), Yu-Waye Chu (Option Excercise at a value of $367 200), Yu-Waye Chu (Sold 46 581 shares of value $2 165 884 )